WB156
WB156 is a dual MDM2 and GSPT1 PROTAC degrader with a DC50 of 23 nM against MDM2. WB156 induces the degradation of MDM2 and GSPT1 via the ubiquitin-proteasome system. WB156 upregulates the levels of p53 and p21, and triggers Apoptosis through the cleavage of PARP and Caspase-3. WB156 can be used in leukemia-related research.
(Pink: MDM2 and GSPT1 ligand (HY-157830); Blue: Cereblon ligand (HY-138793); Black: linker).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2368944-44-7
- Fòrmula: C48H48Cl2N6O5
- Peso molecular:859.84
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas PROTACs
MoreVer todos los productos específicos de isoformas Eukaryotic Release Factor (eRF)
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
|
MDM2 23 nM (DC50) |
eRF3a/GSPT1 |
Cereblon |
Caspase 3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SUP-B15 | IC50 |
0.0002 μM
|
Antiproliferative activity against human SUP-B15 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human SUP-B15 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| NALM-6 | IC50 |
0.0002 μM
|
Antiproliferative activity against human NALM-6 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human NALM-6 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| OCI-AML-3 | IC50 |
3.644 μM
|
Antiproliferative activity against human Oci-AML3 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human Oci-AML3 leukemia cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| SU-DHL-4 | IC50 |
>10 μM
|
Antiproliferative activity against human SU-DHL-4 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human SU-DHL-4 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| MCF7 | IC50 |
>10 μM
|
Antiproliferative activity against human MCF-7 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human MCF-7 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| MDA-MB-231 | IC50 |
>10 μM
|
Antiproliferative activity against human MDA-MB-231 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human MDA-MB-231 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| LNCaP | IC50 |
>10 μM
|
Antiproliferative activity against human LnCaP non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human LnCaP non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| PC-3 | IC50 |
>10 μM
|
Antiproliferative activity against human PC3 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
Antiproliferative activity against human PC3 non-leukemia cancer cells assessed as reduction in cell viability incubated for 72 hrs by Alamar Blue assay.
|
40440791 |
| RS4-11 | IC50 |
3.2 nM
|
Antiproliferative activity against human RS4;11 leukemia cells.
Antiproliferative activity against human RS4;11 leukemia cells.
|
38761584 |
| RS4-11 | DC50 |
23 nM
|
MDM2 protein degradation activity in human RS4;11 leukemia cells.
MDM2 protein degradation activity in human RS4;11 leukemia cells.
|
38761584 |
In Vitro
WB156 (multiple concentrations; 72 h) inhibits proliferation in all tested leukemia cell lines (wild-type and mutant p53) with IC50 values ranging from 0.0002 μM to 3.644 μM, but has no anti-proliferative effect on tested lymphoma, breast, or prostate cancer cell lines[1].
WB156 (100 nM; 3 h, 6 h) induces degradation of MDM2, GSPT1, and GSPT2, and upregulates p53 in MV-4-11 and MOLT-4 leukemia cells[1].
WB156 (0.01-1.0 μM; 20 h) upregulates p53, does not alter MDM2 levels, and degrades GSPT1 in OCI-AML3 cells[1].
WB156 (0.01-1.0 μM; 20 h) degrades both MDM2 and GSPT1 in Kasumi-1 cells[1].
WB156 (0.01-1.0 μM; 20 h) reduces MDM2 levels at 0.1, 1.0 μM, and degrades GSPT1 at 0.01, 0.1, and 1.0 μM in CCRF-CEM cells[1].
WB156 potently inhibits RS4;11 leukemia cell proliferation with an IC50 of 3.2 nM, degrades MDM2 protein with a DC50 of 23 nM, upregulates p53 and p21, and induces apoptosis via PARP and caspase-3 cleavage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:12 leukemia cell lines (RS4;11, MOLT-4, Jurkat, MV-4-11, MOLM-13, Oci-AML3, Kasumi-1, Kasumi-3, CCRF-CEM, THP-1, SUP-B15, NALM-6), 6 non-leukemia cancer cell lines (SU-DHL-4, MCF-7, MDA-MB-231, LnCaP, PC3, 22rv1)
-
Concentration:multiple concentrations (to generate IC50 values)
-
Incubation Time:72 h
-
Result:Exhibited anti-proliferative activity in all 12 leukemia cell lines, with IC50 values ranging from 0.0002 μM to 3.644 μM.
Showed no anti-proliferative activity (IC50 >10 μM) in all 6 tested non-leukemia cancer cell lines.
-
Cell Line:OCI-AML3 acute myeloid leukemia cell line
-
Concentration:0.01-1.0 μM
-
Incubation Time:20 h
-
Result:Did not significantly modulate MDM2 levels at all tested concentrations.
Induced significant upregulation of p53 levels at all tested concentrations.
Significantly reduced GSPT1 levels at all tested concentrations.
-
Cell Line:Kasumi-1 acute myeloid leukemia cell line
-
Concentration:0.01-1.0 μM
-
Incubation Time:20 h
-
Result:Induced degradation of MDM2 at all tested concentrations.
Induced degradation of GSPT1 at all tested concentrations, with the strongest degradation observed at 1.0 μM.
-
Cell Line:CCRF-CEM acute lymphoblastic leukemia cell line
-
Concentration:0.01-1.0 μM
-
Incubation Time:20 h
-
Result:Induced loss of MDM2 at 0.1 μM and 1.0 μM.
Induced degradation of GSPT1 at all tested concentrations (0.01, 0.1, 1.0 μM).
Chemical Information
-
No. CAS 2368944-44-7
-
Peso molecular 859.84
-
Fòrmula C48H48Cl2N6O5
-
SMILES
O=C(N1CCN(CC1)CC#CC2=C3C(C(N(C4C(NC(CC4)=O)=O)C3)=O)=CC=C2)N5[C@H](C6=CC=C(C=C6)Cl)[C@H](C7=CC=C(C=C7)Cl)N=C5C8=C(C=C(C=C8)C(C)(C)C)OCC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Tandon I, et al. Characterization of a dual degrader of MDM2 and GSPT1. European journal of medicinal chemistry. 2025 Oct 05;295:117793. [Content Brief]
[2]. Li H, et al. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy. European journal of medicinal chemistry. 2024 Jun 05;272:116506. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WB156 Related Classifications
HY-174266 Related Classifications
Powered by Bioz